<DOC>
	<DOCNO>NCT01045889</DOCNO>
	<brief_summary>The purpose study evaluate efficacy intensified first-line treatment , conventional chemotherapy ( CHOP ) plus monoclonal antibody anti CD20 , follow high dose chemotherapy PBSC transplantation HIV-related aggressive non-Hodgkin lymphoma `` high risk '' , accord international prognostic index ( IPI ) .</brief_summary>
	<brief_title>High Dose Therapy Peripheral Blood Stem Cell Transplantation HIV Related Non Hodgkin Lymphoma ( NHL ) High Risk</brief_title>
	<detailed_description>HIV associate NHL show particularly aggressive clinical feature bad prognosis compare general population . The recent introduction highly active antiretroviral therapy ( HAART ) improve HIV positive patient ' clinical condition reduce risk opportunistic infection , thus make HIV+ patient similar HIV- patient . Several study show early use ( first line treatment ) high dose chemotherapy ( HDT ) peripheral blood stem cell transplantation ( PBSCT ) superior HIV negative set conventional dose chemotherapy , least patient poor prognostic factor diagnosis . Recently , several experience show feasibility , safety efficacy HDT PBSCT , association HAART , salvage therapy HIV positive patient lymphoma maintain chemosensitive disease first-line treatment failure . It rationale therefore explore use treatment strategy earlier , within upfront treatment HIV-associated lymphoma , patient poor prognostic factor diagnosis , accord international prognostic score ( IPI ) .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Lymphoma , AIDS-Related</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<criteria>HIV positivity `` Large cell '' histology ( DLBCL , Immunoblastic , Plasmablastic , Anaplastic lymphoma ) Age 1860 year Ageadjusted IPI 23 Ann Arbor stage I BIV Written inform consent . Burkitt lymphoma Lymphoblastic lymphoma Primary effusion lymphoma Ageadjusted IPI 01 Performance Status ( WHO ) &gt; 2 ( related lymphoma ) Inadequate cardiac function ( V.E.F . &lt; 50 % ) clinically evident cardiac disease Inadequate pulmonary function ( DLCO &lt; 50 % and/or O2 &lt; 96 % ) Inadequate renal function ( creatinine &gt; 2 mg/dl ) Inadequate liver function ( AST/ALT &gt; 3 ULN and/or PT &lt; 70 % , related lymphoma ) Inadequate marrow function ( neutrophils &lt; 1500/cmm ; platelet &lt; 100.000/cmm , relate lymphoma ) Virologic failure HAART ( include least one NRTI , one NNRTI two PI ) and/or CD4 count &lt; 50/cmm . CNS meningeal lymphoma Active opportunistic infection Pregnancy Other evolutive malignancy ( except localize nonmelanoma skin cancer situ portio carcinoma ) Any condition contraindicate treatment program discretion physician HBsAg positivity active viral replication ( HBVDNA positivity )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>HIV</keyword>
	<keyword>non hodgkin lymphoma</keyword>
	<keyword>peripheral blood stem cell transplantation</keyword>
</DOC>